By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

SHANGHAI, June 29 (Reuters) - Pfizer's ecnoglutide and Innovent Biologics' mazdutide have passed a preliminary review to be ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...

Senator Ron Johnson (R-WI) made controversial claims during a June 2026 Senate hearing, alleging that federal health agencies ...

By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 ...

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...